Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record €8 billion in 2024, it said today. Fuelled by ...

Novo doesn’t charge for incoming or outgoing ACH transfers, incoming domestic or foreign wire transfers, stop payments, debit card replacement, physical checks, bill payments, checks or paper ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Pre-Market: 7:10:04 a.m. EDT ...